메뉴 건너뛰기




Volumn 36, Issue SUPPL.2, 2013, Pages

Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN;

EID: 84890949863     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dcS13-2031     Document Type: Article
Times cited : (80)

References (59)
  • 1
    • 43849085397 scopus 로고    scopus 로고
    • Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects
    • Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008;31:714-719
    • (2008) Diabetes Care , vol.31 , pp. 714-719
    • Juutilainen, A.1    Lehto, S.2    Rönnemaa, T.3    Pyörälä, K.4    Laakso, M.5
  • 2
    • 10344240901 scopus 로고    scopus 로고
    • Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: A double-blind, randomized trial
    • Quartet [corrected] Study Group.
    • Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-6076
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 6068-6076
    • Schernthaner, G.1    Matthews, D.R.2    Charbonnel, B.3    Hanefeld, M.4    Brunetti, P.5
  • 3
    • 21344451651 scopus 로고    scopus 로고
    • Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
    • Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48: 1093-1104
    • (2005) Diabetologia , vol.48 , pp. 1093-1104
    • Charbonnel, B.1    Schernthaner, G.2    Brunetti, P.3
  • 4
    • 84859013614 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus metformin pioglitazone and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study
    • DURATION-4 Study Group.
    • Russell-Jones D, Cuddihy RM, Hanefeld M, et al.; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252-258
    • (2012) Diabetes Care , vol.35 , pp. 252-258
    • Russell-Jones, D.1    Cuddihy, R.M.2    Hanefeld, M.3
  • 5
    • 77957710722 scopus 로고    scopus 로고
    • Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: Comparison with other oral antihyperglycaemic agents
    • Derosa G. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. Drugs 2010;70:1945-1961
    • (2010) Drugs , vol.70 , pp. 1945-1961
    • Derosa, G.1
  • 6
    • 79953232077 scopus 로고    scopus 로고
    • Pioglitazone for diabetes prevention in impaired glucose tolerance
    • ACT NOW Study.
    • DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N EnglJ Med 2011;364:1104-1115
    • (2011) N EnglJ Med , vol.364 , pp. 1104-1115
    • Defronzo, R.A.1    Tripathy, D.2    Schwenke, D.C.3
  • 7
    • 0343485089 scopus 로고    scopus 로고
    • Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: The 22-year follow-up results of the Helsinki Policemen Study
    • Pyörälä M, Miettinen H, Halonen P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000;20:538-544
    • (2000) Arterioscler Thromb Vasc Biol , vol.20 , pp. 538-544
    • Pyörälä, M.1    Miettinen, H.2    Halonen, P.3    Laakso, M.4    Pyörälä, K.5
  • 8
    • 0036633043 scopus 로고    scopus 로고
    • HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: Prospective data from the Verona Diabetes Complications Study
    • Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25:1135-1141
    • (2002) Diabetes Care , vol.25 , pp. 1135-1141
    • Bonora, E.1    Formentini, G.2    Calcaterra, F.3
  • 9
    • 33244464265 scopus 로고    scopus 로고
    • Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: A systematic review
    • Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006;49:434-441
    • (2006) Diabetologia , vol.49 , pp. 434-441
    • Natali, A.1    Ferrannini, E.2
  • 10
    • 0022881373 scopus 로고
    • Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus
    • Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabete Metab 1986; 12:346-350
    • (1986) Diabete Metab , vol.12 , pp. 346-350
    • Prager, R.1    Schernthaner, G.2    Graf, H.3
  • 12
    • 77958529709 scopus 로고    scopus 로고
    • Cardiovascular risk and thiazolidinedionesdwhat do meta-analyses really tell us?
    • Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinedionesdwhat do meta-analyses really tell us? Diabetes Obes Metab 2010;12:1023-1035
    • (2010) Diabetes Obes Metab , vol.12 , pp. 1023-1035
    • Schernthaner, G.1    Chilton, R.J.2
  • 13
    • 35148837113 scopus 로고    scopus 로고
    • Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
    • GLAI Study Investigators.
    • Deeg MA, Buse JB, Goldberg RB, et al.; GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30: 2458-2464
    • (2007) Diabetes Care , vol.30 , pp. 2458-2464
    • Deeg, M.A.1    Buse, J.B.2    Goldberg, R.B.3
  • 14
    • 77954988618 scopus 로고    scopus 로고
    • Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
    • Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304:411-418
    • (2010) JAMA , vol.304 , pp. 411-418
    • Graham, D.J.1    Ouellet-Hellstrom, R.2    Macurdy, T.E.3
  • 15
    • 84872127720 scopus 로고    scopus 로고
    • A new "comparative Effectiveness" assessment strategy using the THIN database: Comparison of the cardiac complications of pioglitazone and rosiglitazone
    • Tannen R, Xie D, Wang X, Yu M, Weiner MG. A new "Comparative Effectiveness" assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiol Drug Saf 2013;22: 86-97
    • (2013) Pharmacoepidemiol Drug Saf , vol.22 , pp. 86-97
    • Tannen, R.1    Xie, D.2    Wang, X.3    Yu, M.4    Weiner, M.G.5
  • 16
    • 34250723983 scopus 로고    scopus 로고
    • Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metfor-min
    • Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metfor-min. Hypertens Res 2007;30:387-394
    • (2007) Hypertens Res , vol.30 , pp. 387-394
    • Derosa, G.1    Fogari, E.2    Cicero, A.F.3
  • 17
    • 65649084066 scopus 로고    scopus 로고
    • Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
    • Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 2009;63:912-929
    • (2009) Int J Clin Pract , vol.63 , pp. 912-929
    • Schernthaner, G.1
  • 18
    • 77957742069 scopus 로고    scopus 로고
    • Severe hypoglycemia and risks of vascular events and death
    • ADVANCE Collaborative Group.
    • Zoungas S, Patel A, Chalmers J, et al.; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-1418
    • (2010) N Engl J Med , vol.363 , pp. 1410-1418
    • Zoungas, S.1    Patel, A.2    Chalmers, J.3
  • 19
    • 75749145810 scopus 로고    scopus 로고
    • Survival as a function of HbA1c in people with type 2 diabetes: A retrospective cohort study
    • Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2012;375:481-489
    • (2012) Lancet , vol.375 , pp. 481-489
    • Currie, C.J.1    Peters, J.R.2    Tynan, A.3
  • 20
    • 84862108594 scopus 로고    scopus 로고
    • Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes
    • Zhao Y, Campbell CR, Fonseca V, Shi L. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care 2012;35:1126-1132
    • (2012) Diabetes Care , vol.35 , pp. 1126-1132
    • Zhao, Y.1    Campbell, C.R.2    Fonseca, V.3    Shi, L.4
  • 21
    • 26244453309 scopus 로고    scopus 로고
    • Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial
    • PROactive investigators.
    • Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366: 1279-1289
    • (2005) Lancet , vol.366 , pp. 1279-1289
    • Dormandy, J.A.1    Charbonnel, B.2    Eckland, D.J.3
  • 22
    • 33847675510 scopus 로고    scopus 로고
    • The effect of pio-glitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study
    • PROactive Investigators.
    • Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pio-glitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-1780
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1772-1780
    • Erdmann, E.1    Dormandy, J.A.2    Charbonnel, B.3    Massi-Benedetti, M.4    Moules, I.K.5    Skene, A.M.6
  • 23
    • 33947539408 scopus 로고    scopus 로고
    • Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04)
    • PROactive Investigators
    • Wilcox R, Bousser MG, Betteridge DJ, et al.; PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-873
    • (2007) Stroke , vol.38 , pp. 865-873
    • Wilcox, R.1    Bousser, M.G.2    Betteridge, D.J.3
  • 24
    • 57649213646 scopus 로고    scopus 로고
    • Impact of peripheral arterial disease in patients with diabetesdresults from PROactive (PROactive 11)
    • PROactive investigators
    • Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; PROactive investigators. Impact of peripheral arterial disease in patients with diabetesdresults from PROactive (PROactive 11). Atherosclerosis 2009;202:272-281
    • (2009) Atherosclerosis , vol.202 , pp. 272-281
    • Dormandy, J.A.1    Betteridge, D.J.2    Schernthaner, G.3    Pirags, V.4    Norgren, L.5
  • 25
    • 33845400193 scopus 로고    scopus 로고
    • Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: A randomized trial
    • Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-2581
    • (2006) JAMA , vol.296 , pp. 2572-2581
    • Mazzone, T.1    Meyer, P.M.2    Feinstein, S.B.3
  • 26
    • 41649084422 scopus 로고    scopus 로고
    • Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial
    • PERISCOPE Investigators
    • Nissen SE, Nicholls SJ, Wolski K, et al.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299: 1561-1573
    • (2008) JAMA , vol.299 , pp. 1561-1573
    • Nissen, S.E.1    Nicholls, S.J.2    Wolski, K.3
  • 28
    • 64949086377 scopus 로고    scopus 로고
    • Thiazolidinedione use is associated with better survival in hemo-dialysis patients with non-insulin dependent diabetes
    • Brunelli SM, Thadhani R, Ikizler TA, Feldman HI. Thiazolidinedione use is associated with better survival in hemo-dialysis patients with non-insulin dependent diabetes. Kidney Int 2009;75: 961-968
    • (2009) Kidney Int , vol.75 , pp. 961-968
    • Brunelli, S.M.1    Thadhani, R.2    Ikizler, T.A.3    Feldman, H.I.4
  • 29
    • 84860117993 scopus 로고    scopus 로고
    • Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK General Practice Research Database
    • Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK General Practice Research Database. BMJ 2009;339:b4731
    • (2009) BMJ , vol.339
    • Tzoulaki, I.1    Molokhia, M.2    Curcin, V.3
  • 30
    • 34548590934 scopus 로고    scopus 로고
    • Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
    • Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-1188
    • (2007) JAMA , vol.298 , pp. 1180-1188
    • Lincoff, A.M.1    Wolski, K.2    Nicholls, S.J.3    Nissen, S.E.4
  • 31
    • 84866138849 scopus 로고    scopus 로고
    • Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials
    • Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012;55:2593-2603
    • (2012) Diabetologia , vol.55 , pp. 2593-2603
    • Stevens, R.J.1    Ali, R.2    Bankhead, C.R.3
  • 32
    • 84864285795 scopus 로고    scopus 로고
    • Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (
    • ADA)
    • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-1596
    • (2012) And the European Association for the Study of Diabetes (EASD). Diabetologia , vol.55 , pp. 1577-1596
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3
  • 33
    • 84870753442 scopus 로고    scopus 로고
    • What next after metformin? A retrospective evalua-tionof the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes
    • Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evalua-tionof the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012;97: 4605-4612
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. 4605-4612
    • Morgan, C.L.1    Poole, C.D.2    Evans, M.3    Barnett, A.H.4    Jenkins-Jones, S.5    Currie, C.J.6
  • 34
    • 84870248203 scopus 로고    scopus 로고
    • Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: An analysis of the PROactive study population
    • Doehner W, Erdmann E, Cairns R, et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol 2012;162:20-26
    • (2012) Int J Cardiol , vol.162 , pp. 20-26
    • Doehner, W.1    Erdmann, E.2    Cairns, R.3
  • 35
    • 50649121372 scopus 로고    scopus 로고
    • Monitoring the safety of pioglitazone: Results of a prescription-event monitoring study of 12, 772 patients in England
    • Kasliwal R, Wilton LV, Shakir SA. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12, 772 patients in England. Drug Saf 2008;31:839-850
    • (2008) Drug Saf , vol.31 , pp. 839-850
    • Kasliwal, R.1    Wilton, L.V.2    Shakir, S.A.3
  • 36
    • 34648824645 scopus 로고    scopus 로고
    • Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: Data from the PROactive study (PROactive 08)
    • PROactive investigators.
    • Erdmann E, Charbonnel B, Wilcox RG, et al.; PROactive investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30: 2773-2778
    • (2007) Diabetes Care , vol.30 , pp. 2773-2778
    • Erdmann, E.1    Charbonnel, B.2    Wilcox, R.G.3
  • 38
    • 23844472901 scopus 로고    scopus 로고
    • Thiazoli-dinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption
    • Guan Y, Hao C, Cha DR, et al. Thiazoli-dinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-866
    • (2005) Nat Med , vol.11 , pp. 861-866
    • Guan, Y.1    Hao, C.2    Cha, D.R.3
  • 39
    • 79958816344 scopus 로고    scopus 로고
    • Thiazolidinediones and fracture risk in patients with Type 2 diabetes
    • Betteridge DJ. Thiazolidinediones and fracture risk in patients with Type 2 diabetes. Diabet Med 2011;28:759-771
    • (2011) Diabet Med , vol.28 , pp. 759-771
    • Betteridge, D.J.1
  • 40
    • 84867571503 scopus 로고    scopus 로고
    • Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
    • Scottish Diabetes Research Network Epidemiology Group.
    • Colhoun HM, Livingstone SJ, Looker HC, et al.; Scottish Diabetes Research Network Epidemiology Group. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia 2012;55:2929-2937
    • (2012) Diabetologia , vol.55 , pp. 2929-2937
    • Colhoun, H.M.1    Livingstone, S.J.2    Looker, H.C.3
  • 41
    • 63849148589 scopus 로고    scopus 로고
    • Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: An overview of data from PROactive
    • PROactive investigators
    • Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009;32: 187-202
    • (2009) Drug Saf , vol.32 , pp. 187-202
    • Dormandy, J.1    Bhattacharya, M.2    Van Troostenburg De Bruyn, A.R.3
  • 42
    • 58849094131 scopus 로고    scopus 로고
    • Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis
    • Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32-39
    • (2009) CMAJ , vol.180 , pp. 32-39
    • Loke, Y.K.1    Singh, S.2    Furberg, C.D.3
  • 43
    • 37749034527 scopus 로고    scopus 로고
    • Skeletal consequences of thiazoli-dinedione therapy
    • Grey A. Skeletal consequences of thiazoli-dinedione therapy. Osteoporos Int 2008; 19:129-137
    • (2008) Osteoporos Int , vol.19 , pp. 129-137
    • Grey, A.1
  • 44
    • 84863694353 scopus 로고    scopus 로고
    • Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes
    • Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med 2012;172:1005-1011
    • (2012) Arch Intern Med , vol.172 , pp. 1005-1011
    • Idris, I.1    Warren, G.2    Donnelly, R.3
  • 45
    • 62649174048 scopus 로고    scopus 로고
    • Glitazone use associated with diabetic macular edema
    • e1
    • Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009;147:583-586, e1
    • (2009) Am J Ophthalmol , vol.147 , pp. 583-586
    • Fong, D.S.1    Contreras, R.2
  • 46
    • 79960720836 scopus 로고    scopus 로고
    • Takeda Pharmaceuticals, Accessed 29 January 2013
    • Takeda Pharmaceuticals. Highlights of prescribing information [Internet], 2011. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 021073s035lbl.pdf. Accessed 29 January 2013
    • (2011) Highlights of Prescribing Information [Internet]
  • 47
    • 79956217900 scopus 로고    scopus 로고
    • Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study
    • Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-922
    • (2011) Diabetes Care , vol.34 , pp. 916-922
    • Lewis, J.D.1    Ferrara, A.2    Peng, T.3
  • 48
    • 84891799937 scopus 로고    scopus 로고
    • Pioglitazone HCl. (ACTOS). Clinical study no. 01-03-TL-OPI-524. Cohort study of pioglitazone and bladder cancer in patients with diabetes fourth interim analysis (8-year) report with data from January 1, 1997 to December 31, 2010 [article online], Accessed 15 March 2013
    • Pioglitazone HCl. (ACTOS). Clinical study no. 01-03-TL-OPI-524. Cohort study of pioglitazone and bladder cancer in patients with diabetes fourth interim analysis (8-year) report with data from January 1, 1997 to December 31, 2010 [article online], 2011. Available from http://www.pharmatelligence.co.uk/ static/documents/01-03-tl-opi-524-8-year-interim-report.pdf. Accessed 15 March 2013
    • (2011)
  • 49
    • 84866358522 scopus 로고    scopus 로고
    • Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study
    • Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55: 1953-1962
    • (2012) Diabetologia , vol.55 , pp. 1953-1962
    • Neumann, A.1    Weill, A.2    Ricordeau, P.3    Fagot, J.P.4    Alla, F.5    Allemand, H.6
  • 50
    • 84891752477 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration. FDA Drug Safety Communication. update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer [article online], Accessed 29 January 2013
    • U.S. Food and Drug Administration. FDA Drug Safety Communication. update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer [article online], 2011. Available from http://www. fda.gov/drugs/ drugsafety/ucm259150.htm. Accessed 29 January 2013
    • (2011)
  • 51
    • 84862684037 scopus 로고    scopus 로고
    • The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case-control study
    • Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344: e3645
    • (2012) BMJ , vol.344
    • Azoulay, L.1    Yin, H.2    Filion, K.B.3
  • 52
    • 84871113059 scopus 로고    scopus 로고
    • Pioglitazone and bladder cancer: A propensity score matched cohort study
    • Wei L, MacDonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013;75:254-259
    • (2013) Br J Clin Pharmacol , vol.75 , pp. 254-259
    • Wei, L.1    Macdonald, T.M.2    Mackenzie, I.S.3
  • 53
    • 84865858873 scopus 로고    scopus 로고
    • Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis
    • Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184:E675-E683
    • (2012) CMAJ , vol.184
    • Colmers, I.N.1    Bowker, S.L.2    Majumdar, S.R.3    Johnson, J.A.4
  • 54
    • 84867395333 scopus 로고    scopus 로고
    • Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis
    • Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2012;98:159-163
    • (2012) Diabetes Res Clin Pract , vol.98 , pp. 159-163
    • Zhu, Z.1    Shen, Z.2    Lu, Y.3    Zhong, S.4    Xu, C.5
  • 55
    • 84856101775 scopus 로고    scopus 로고
    • The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipid-emia, and gout in Taiwanese patients
    • Lee MY, Lin KD, Hsiao PJ, Shin SJ. The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipid-emia, and gout in Taiwanese patients. Metabolism 2012;61:242-249
    • (2012) Metabolism , vol.61 , pp. 242-249
    • Lee, M.Y.1    Lin, K.D.2    Hsiao, P.J.3    Shin, S.J.4
  • 56
    • 84859760984 scopus 로고    scopus 로고
    • Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mel-litus
    • Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mel-litus. Hepatology 2012;55:1462-1472
    • (2012) Hepatology , vol.55 , pp. 1462-1472
    • Chang, C.H.1    Lin, J.W.2    Wu, L.C.3    Lai, M.S.4    Chuang, L.M.5    Chan, K.A.6
  • 57
    • 84873859028 scopus 로고    scopus 로고
    • Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: A nationwide, population-based, case-control study
    • Health Data Analysis in Taiwan Research Group.
    • Chen SW, Tsan YT, Chen JD, et al.; Health Data Analysis in Taiwan Research Group. Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study. Diabetes Care 2013; 36:369-375
    • (2013) Diabetes Care , vol.36 , pp. 369-375
    • Chen, S.W.1    Tsan, Y.T.2    Chen, J.D.3
  • 58
    • 34248192254 scopus 로고    scopus 로고
    • Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
    • Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25:1476-1481
    • (2007) J Clin Oncol , vol.25 , pp. 1476-1481
    • Govindarajan, R.1    Ratnasinghe, L.2    Simmons, D.L.3
  • 59
    • 84866156935 scopus 로고    scopus 로고
    • The effect of met-formin and thiazolidinedione use on lung cancer in diabetics
    • Mazzone PJ, Rai H, Beukemann M, Xu M, Jain AK, Sasidhar M. The effect of met-formin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2012;12: 410
    • (2012) BMC Cancer , vol.12 , pp. 410
    • Mazzone, P.J.1    Rai, H.2    Beukemann, M.3    Xu, M.4    Jain, A.K.5    Sasidhar, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.